Serum alpha-tocopherol, retinol and neopterin during paclitaxel/carboplatin chemotherapy

Anticancer Res. 2007 Nov-Dec;27(6C):4397-401.

Abstract

Background: Disorders of antioxidant balance are considered to be involved in the toxicity associated with radiotherapy or chemotherapy.

Patients and methods: Serum alpha-tocopherol and retinol were determined, by high performance liquid chromatography, before and during therapy with a combination of paclitaxel and carboplatin in 28 patients with breast and ovarian cancer. Serum neopterin and cholesterol were measured using a radioimmunoassay and enzymatic colorimetric method, respectively.

Results: Compared to pretreatment concentrations, a significant increase was observed in serum alpha-tocopherol and retinol concentrations during therapy that was associated with decreased serum neopterin concentrations. Serum alpha-tocopherol concentrations were significantly higher during therapy in patients who did not experience serious toxicity.

Conclusion: An increase in alpha-tocopherol and retinol during therapy with combination paclitaxel/carboplatin may be explained by inhibition of systemic immune activation secondary to control of the tumor with effective chemotherapy. Lower alpha-tocopherol concentrations were associated with the toxicity of therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / blood
  • Breast Neoplasms / drug therapy*
  • Carboplatin / administration & dosage
  • Chromatography, High Pressure Liquid
  • Female
  • Humans
  • Middle Aged
  • Neopterin / blood*
  • Ovarian Neoplasms / blood
  • Ovarian Neoplasms / drug therapy*
  • Paclitaxel / administration & dosage
  • Vitamin A / blood*
  • alpha-Tocopherol / blood*

Substances

  • Vitamin A
  • Neopterin
  • Carboplatin
  • alpha-Tocopherol
  • Paclitaxel